Fairmount Funds Management LLC: 13F holdings, Q2 2026
Hedge fund · SEC EDGAR filings (CIK 1802528) · Explore on the interactive board
Fairmount Funds Management LLC disclosed 12 US equity positions worth $1.5bn in its Q2 2026 13F filing (holdings as of June 30, 2026, filed August 14, 2026). Its largest position is ORKA at 23.3% of the reported book, followed by DNTH, DMRA. The top ten holdings are 97.7% of the book, and the portfolio behaves like about 7 equal-weight positions. Versus the prior filing it opened 1 new position, added to 1, reduced 0 and exited 1. Note: this manager's most recent filing is 3934 quarters behind the newest quarter on file, so these figures are history rather than current positioning.
What does Fairmount Funds Management LLC own? Top holdings as of June 30, 2026
Change is measured in shares against the previous filing (Q1 2026), so price moves do not read as decisions. This quarter: 1 new, 1 added, 0 reduced, 1 exited.
| # | Stock | Sector | Weight | Value | Shares | Δ shares | Action |
|---|---|---|---|---|---|---|---|
| 1 | ORKA ORUKA THERAPEUTICS INC | Healthcare | 23.3% | $352.6m | 3,705,262 | 0% | held |
| 2 | DNTH DIANTHUS THERAPEUTICS INC | Healthcare | 16.3% | $247.3m | 2,537,191 | 0% | held |
| 3 | DMRA DAMORA THERAPEUTICS INC | Healthcare | 15.0% | $226.6m | 8,713,000 | 0% | held |
| 4 | COGT COGENT BIOSCIENCES INC | Healthcare | 14.1% | $213.0m | 5,503,418 | 0% | held |
| 5 | JBIO JADE BIOSCIENCES INC | Healthcare | 6.7% | $101.2m | 4,553,494 | 0% | held |
| 6 | ELVN ENLIVEN THERAPEUTICS INC | Healthcare | 6.2% | $94.2m | 1,855,644 | 0% | held |
| 7 | VRDN VIRIDIAN THERAPEUTICS INC | Healthcare | 6.2% | $93.5m | 5,090,928 | 30% | added |
| 8 | ZBIO ZENAS BIOPHARMA INC | 4.0% | $59.9m | 2,359,025 | 0% | held | |
| 9 | CBIO CRESCENT BIOPHARMA INC. | 3.3% | $49.5m | 2,747,866 | 0% | held | |
| 10 | APGE APOGEE THERAPEUTICS INC | Healthcare | 2.6% | $39.6m | 298,647 | 0% | held |
| 11 | FTH FAETH THERAPEUTICS INC | 1.2% | $18.1m | 722,020 | – | new | |
| 12 | IKT INHIBIKASE THERAPEUTICS INC | 1.2% | $17.5m | 8,625,000 | 0% | held |
What did Fairmount Funds Management LLC sell? Positions exited since the previous filing
| Stock | Prior weight | Prior value |
|---|---|---|
| SYRE SPYRE THERAPEUTICS INC | 100.0% | $202.7m |
Sector mix
| Sector | Weight |
|---|---|
| Healthcare | 90.4% |
Sectors cover positions whose ticker resolved to a sector; the remainder is unclassified, not cash.
Filing history
How concentrated is Fairmount Funds Management LLC's portfolio?
Across every quarter Fairmount Funds Management LLC has filed, its median largest position is 19.8% of the book and its median top-ten weight is 97.4%, which WhaleCreep classifies as concentrated (the gate is a median largest position of 5%). Of 1.0 completed holding spells, the median lasted 1.0 quarters; 12.0 positions are still open and their final length is unknown.